Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD.

Journal Article (Journal Article)

Chronic GvHD (cGvHD) remains a prominent barrier to allogeneic hematopoietic stem cell transplantion as the leading cause of non-relapse mortality and significant morbidity. Tremendous progress has been achieved in both understanding of pathophysiology and the development of new therapies for cGvHD. While our field has historically approached treatment from an empiric position, research performed at the bedside and bench has elucidated some of the complex pathophysiology of cGvHD. From the clinical perspective, there is significant variability of disease manifestations between individual patients, pointing to diverse biological underpinnings. Capitalizing on progress made to date, the field is now focused on establishing personalized treatment approaches. The manuscript's intent is to concisely review recent knowledge gained and formulate a path towards patient-specific cGvHD therapy.

Full Text

Duke Authors

Cited Authors

  • Buxbaum, NP; Socié, G; Hill, GR; MacDonald, KP; Tkachev, V; Teshima, T; Lee, SJ; Ritz, J; Sarantopoulos, S; Luznik, L; Zeng, D; Paczesny, S; Martin, PJ; Pavletic, SZ; Schultz, KR; Blazar, BR

Published Date

  • November 2, 2022

Published In

  • Blood Adv

PubMed ID

  • 36322878

Electronic International Standard Serial Number (EISSN)

  • 2473-9537

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2022007611


  • eng

Conference Location

  • United States